Do analysts prefer ARTL or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ARTL or PRFX more profitable?

PainReform's return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -518.27% -194.29% PainReform N/A N/A N/A

Does the media favor ARTL or PRFX?

In the previous week, Artelo Biosciences had 1 more articles in the media than PainReform. MarketBeat recorded 2 mentions for Artelo Biosciences and 1 mentions for PainReform. PainReform's average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.50 indicating that PainReform is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative PainReform 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PRFX or NXTS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexentis Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PRFX or NXTS more profitable?

PainReform's return on equity of 0.00% beat Nexentis Technologies' return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Nexentis Technologies N/A -304.79% -178.91%

Does the media refer more to PRFX or NXTS?

In the previous week, PainReform and PainReform both had 1 articles in the media. PainReform's average media sentiment score of 0.00 equaled Nexentis Technologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PainReform 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nexentis Technologies 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CASI or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CASI or PRFX more profitable?

PainReform has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals -183.93% N/A -131.54% PainReform N/A N/A N/A

Do analysts recommend PRFX or CANF?

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 1,772.34%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than PainReform. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is PRFX or CANF more profitable?

Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Can-Fite BioPharma N/A N/A N/A

Does the media prefer PRFX or CANF?

In the previous week, Can-Fite BioPharma had 3 more articles in the media than PainReform. MarketBeat recorded 4 mentions for Can-Fite BioPharma and 1 mentions for PainReform. Can-Fite BioPharma's average media sentiment score of 0.20 beat PainReform's score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PainReform 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Can-Fite BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VCNX or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VCNX or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% PainReform N/A N/A N/A

PainReform (PRFX) Competitors

$0.98 +0.00 (+0.48%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$0.95 -0.03 (-3.08%)

As of 06:40 AM Eastern

Compare

PRFX vs. ARTL, NXTS, CASI, CANF, and VCNX

Should you buy PainReform stock or one of its competitors? PainReform's main competitors and comparable companies include Artelo Biosciences (ARTL), Nexentis Technologies (NXTS), CASI Pharmaceuticals (CASI), Can-Fite BioPharma (CANF), and Vaccinex (VCNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PainReform compare to Artelo Biosciences?

Artelo Biosciences (NASDAQ:ARTL) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

PainReform has higher revenue and earnings than Artelo Biosciences. Artelo Biosciences is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$16.80	N/A
PainReform	$20K	42.60	-$5.02M	-$736.66	N/A

Artelo Biosciences has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, PainReform has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

PainReform's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-518.27%	-194.29%
PainReform	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Artelo Biosciences had 1 more articles in the media than PainReform. MarketBeat recorded 2 mentions for Artelo Biosciences and 1 mentions for PainReform. PainReform's average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.50 indicating that PainReform is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
PainReform	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

PainReform beats Artelo Biosciences on 9 of the 12 factors compared between the two stocks.

How does PainReform compare to Nexentis Technologies?

PainReform (NASDAQ:PRFX) and Nexentis Technologies (NASDAQ:NXTS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexentis Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform's return on equity of 0.00% beat Nexentis Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Nexentis Technologies	N/A	-304.79%	-178.91%

In the previous week, PainReform and PainReform both had 1 articles in the media. PainReform's average media sentiment score of 0.00 equaled Nexentis Technologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PainReform	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nexentis Technologies	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nexentis Technologies has higher revenue and earnings than PainReform. Nexentis Technologies is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	42.60	-$5.02M	-$736.66	N/A
Nexentis Technologies	$210K	11.60	-$4M	-$96.07	N/A

PainReform has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Nexentis Technologies has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

37.3% of PainReform shares are held by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Comparatively, 6.5% of Nexentis Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

PainReform and Nexentis Technologies tied by winning 5 of the 10 factors compared between the two stocks.

How does PainReform compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
PainReform	N/A	N/A	N/A

CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

In the previous week, PainReform had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for PainReform and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
PainReform	Neutral

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PainReform has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
PainReform	$20K	42.60	-$5.02M	-$736.66	N/A

Summary

PainReform beats CASI Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does PainReform compare to Can-Fite BioPharma?

PainReform (NASDAQ:PRFX) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

PainReform has higher earnings, but lower revenue than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	42.60	-$5.02M	-$736.66	N/A
Can-Fite BioPharma	$405K	3.80	-$7.63M	-$22.80	N/A

In the previous week, Can-Fite BioPharma had 3 more articles in the media than PainReform. MarketBeat recorded 4 mentions for Can-Fite BioPharma and 1 mentions for PainReform. Can-Fite BioPharma's average media sentiment score of 0.20 beat PainReform's score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PainReform	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Can-Fite BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Can-Fite BioPharma	N/A	N/A	N/A

37.3% of PainReform shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

PainReform has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 1,772.34%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Can-Fite BioPharma beats PainReform on 8 of the 13 factors compared between the two stocks.

How does PainReform compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
PainReform	N/A	N/A	N/A

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

PainReform has lower revenue, but higher earnings than Vaccinex. Vaccinex is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	5.03	-$20.25M	-$48.27	N/A
PainReform	$20K	42.60	-$5.02M	-$736.66	N/A

Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, PainReform has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PainReform had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for PainReform and 0 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
PainReform	Neutral

Summary

PainReform beats Vaccinex on 6 of the 11 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRFX vs. The Competition

Export

Metric	PainReform	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$850K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.28	273.30	25.25
Price / Sales	42.60	755.95	618.15	97.66
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.04	12.32	12.89	6.14
Net Income	-$5.02M	$2.82B	$3.47B	$349.01M
7 Day Performance	1.88%	2.58%	0.53%	-0.31%
1 Month Performance	-13.35%	6.94%	5.64%	0.64%
1 Year Performance	-87.95%	9.44%	25.31%	14.83%

PainReform Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRFX PainReform	0.359 of 5 stars	$0.98 +0.5%	N/A	-86.1%	$850K	$20K	N/A	4	News Coverage Gap Down
ARTL Artelo Biosciences	0.9061 of 5 stars	$0.71 -0.9%	N/A	-97.4%	$3.27M	N/A	N/A	5
NXTS Nexentis Technologies	0.2525 of 5 stars	$1.88 +1.6%	N/A	-96.8%	$2.73M	N/A	N/A	2	News Coverage Positive News Gap Up
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
CANF Can-Fite BioPharma	2.2373 of 5 stars	$3.32 flat	$44.00 +1,225.3%	-82.2%	$2.18M	$405K	N/A	8

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRFX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PainReform (PRFX) Competitors

PRFX vs. ARTL, NXTS, CASI, CANF, and VCNX

How does PainReform compare to Artelo Biosciences?

Summary

How does PainReform compare to Nexentis Technologies?

Summary

How does PainReform compare to CASI Pharmaceuticals?

Summary

How does PainReform compare to Can-Fite BioPharma?

Summary

How does PainReform compare to Vaccinex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PainReform (PRFX) Competitors

PRFX vs. ARTL, NXTS, CASI, CANF, and VCNX

How does PainReform compare to Artelo Biosciences?

Which has higher earnings and valuation, ARTL or PRFX?

Which has more risk & volatility, ARTL or PRFX?

Is ARTL or PRFX more profitable?

Do analysts prefer ARTL or PRFX?

Does the media favor ARTL or PRFX?

Do insiders & institutionals believe in ARTL or PRFX?

Summary

How does PainReform compare to Nexentis Technologies?

Do analysts recommend PRFX or NXTS?

Is PRFX or NXTS more profitable?

Does the media refer more to PRFX or NXTS?

Which has preferable earnings & valuation, PRFX or NXTS?

Which has more risk and volatility, PRFX or NXTS?

Do institutionals and insiders have more ownership in PRFX or NXTS?

Summary

How does PainReform compare to CASI Pharmaceuticals?

Do analysts rate CASI or PRFX?

Is CASI or PRFX more profitable?

Which has more risk and volatility, CASI or PRFX?

Does the media refer more to CASI or PRFX?

Do institutionals & insiders hold more shares of CASI or PRFX?

Which has preferable valuation & earnings, CASI or PRFX?

Summary

How does PainReform compare to Can-Fite BioPharma?

Which has better valuation & earnings, PRFX or CANF?

Does the media prefer PRFX or CANF?

Is PRFX or CANF more profitable?

Do insiders & institutionals hold more shares of PRFX or CANF?

Which has more volatility & risk, PRFX or CANF?

Do analysts recommend PRFX or CANF?

Summary

How does PainReform compare to Vaccinex?

Is VCNX or PRFX more profitable?

Do institutionals and insiders hold more shares of VCNX or PRFX?

Which has better valuation & earnings, VCNX or PRFX?

Which has more volatility & risk, VCNX or PRFX?

Do analysts rate VCNX or PRFX?

Does the media prefer VCNX or PRFX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools